[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@stellanewslife Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1292752935533686785.png) @stellanewslife STELLANEWS.LIFE

STELLANEWS.LIFE posts on X about $abbv, $4506t, $8053t, as one the most. They currently have XXX followers and XX posts still getting attention that total XX engagements in the last XX hours.

### Engagements: XX [#](/creator/twitter::1292752935533686785/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1292752935533686785/c:line/m:interactions.svg)

- X Week XXXXX +192%
- X Month XXXXX +338%
- X Months XXXXXX +157%
- X Year XXXXXX +3,683%

### Mentions: X [#](/creator/twitter::1292752935533686785/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1292752935533686785/c:line/m:posts_active.svg)

- X Week XX +74%
- X Month XX +85%
- X Months XXX +110%
- X Year XXX +3,357%

### Followers: XXX [#](/creator/twitter::1292752935533686785/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1292752935533686785/c:line/m:followers.svg)

- X Week XXX +1.70%
- X Month XXX +2.20%
- X Months XXX +13%
- X Year XXX +24%

### CreatorRank: undefined [#](/creator/twitter::1292752935533686785/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1292752935533686785/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::1292752935533686785/influence)
---

**Social category influence**
[stocks](/list/stocks)  XXXX% [currencies](/list/currencies)  XXXX% [countries](/list/countries)  XXXX%

**Social topic influence**
[$abbv](/topic/$abbv) #75, [$4506t](/topic/$4506t) 3.7%, [$8053t](/topic/$8053t) 3.7%, [as one](/topic/as-one) 1.85%, [$4523t](/topic/$4523t) 1.85%, [san diego](/topic/san-diego) 1.85%, [momentum](/topic/momentum) 1.85%, [announces](/topic/announces) 1.85%, [japan](/topic/japan) 1.85%, [$4503t](/topic/$4503t) XXXX%

**Top assets mentioned**
[AbbVie Inc (ABBV)](/topic/$abbv)
### Top Social Posts [#](/creator/twitter::1292752935533686785/posts)
---
Top posts by engagements in the last XX hours

"LEQEMBI IQLIK selected as one of TIME's Best Inventions of 2025 in the Healthcare category #LEQEMBI #lecanemab #TIMEBestInventions #Alzheimers #AutoInjector #Eisai #Biogen #Aducanumab #HealthcareInnovation #NeurodegenerativeDiseases #HomeCare #DementiaTreatment"  
[X Link](https://x.com/stellanewslife/status/1979539931220648336) [@stellanewslife](/creator/x/stellanewslife) 2025-10-18T13:27Z XXX followers, XX engagements


"Grifols expands U.S. diagnostic manufacturing with new facility in San Diego #Grifols #SanDiego #Diagnostics #BloodTyping #DGCard #RRBCs #TransfusionMedicine #FDAapproval #HealthcareManufacturing #MedTech #BiotechNews #Plasma #MedicalInnovation"  
[X Link](https://x.com/stellanewslife/status/1979540292450808287) [@stellanewslife](/creator/x/stellanewslife) 2025-10-18T13:29Z XXX followers, XXX engagements


"Bristol Myers Squibb highlights long-term Opdivo data & dual-targeting ADC at ESMO 2025 Iza-bren (EGFRHER3 ADC) and 50+ trials show major momentum in BMSs oncology pipeline. 🔗 #ImmunoOncology #ESMO2025 #ADCTherapy"  
[X Link](https://x.com/stellanewslife/status/1979617503925199108) [@stellanewslife](/creator/x/stellanewslife) 2025-10-18T18:36Z XXX followers, XXX engagements


"🚀 Promising ADC data from AbbVie at ESMO 2025: Temab-A (anti-c-Met ADC): ORR of up to XX% in NSCLC and XX% in MET-amplified tumors Shows strong potential in CRC pancreatic cancer ABBV-706 (anti-SEZ6 ADC): ctDNA clearance in SCLC correlates with improved PFS/OS 🔗 Full report: #ADC #ImmunoOncology #ESMO2025 #SolidTumors #AbbVie"  
[X Link](https://x.com/stellanewslife/status/1979622828682199469) [@stellanewslife](/creator/x/stellanewslife) 2025-10-18T18:57Z XXX followers, XXX engagements


"🧠 AbbVie acquires bretisilocin a novel short-acting 5-HT2A agonist in Phase X for major depressive disorder. Designed to minimize the challenges of classic psychedelics (long duration management issues) while maintaining rapid antidepressant effects. 🔗 Details: #MentalHealth #Depression #PsychedelicMedicine #AbbVie"  
[X Link](https://x.com/stellanewslife/status/1979623465595605287) [@stellanewslife](/creator/x/stellanewslife) 2025-10-18T18:59Z XXX followers, XX engagements


"Bristol Myers Squibb and TV host Gail Simmons launch COBENFY Connections a new initiative tackling schizophrenia stigma through stories of connection support and hope. #MentalHealth #SchizophreniaAwareness #Support"  
[X Link](https://x.com/stellanewslife/status/1976994024923009308) [@stellanewslife](/creator/x/stellanewslife) 2025-10-11T12:51Z XXX followers, XXX engagements


"Sumitomo Pharma announces latest clinical data for enzomenib (DSP-5336) at the Japanese Society of Hematology (JSH) 2025 Annual Meeting #enzomenib #DSP5336 #nuvisertib #TP3654 #MyeloidLeukemia #AML #MeninInhibitor #PIM1inhibitor #Myelofibrosis #SumitomoPharma #JSH2025 #RareDiseases #TargetedTherapy #Hematology"  
[X Link](https://x.com/stellanewslife/status/1979539003713233190) [@stellanewslife](/creator/x/stellanewslife) 2025-10-18T13:24Z XXX followers, XX engagements


"Sumitomo Pharma and Novo Nordisk Pharma announce promotional partnership for anti-obesity drug Wegovy in Japan #Wegovy #Semaglutide #GLP1 #ObesityTreatment #SumitomoPharma #NovoNordisk #JapanPharma #WeeklyInjection #ChronicDiseaseCare #MedicalPromotion #PharmaAlliance #ObesityAwareness"  
[X Link](https://x.com/stellanewslife/status/1979539361122381977) [@stellanewslife](/creator/x/stellanewslife) 2025-10-18T13:25Z XXX followers, XX engagements


"Regeneron Showcases Oncology Pipeline at ESMO 2025 Highlighting Libtayo Every-6-Week Dosing and Novel Cancer Approaches #Regeneron #ESMO2025 #Oncology #CancerResearch #Libtayo #Immunotherapy #Biotech #ClinicalTrials #CancerCare"  
[X Link](https://x.com/stellanewslife/status/1979541616613560491) [@stellanewslife](/creator/x/stellanewslife) 2025-10-18T13:34Z XXX followers, XXX engagements


"Libtayo (cemiplimab) Receives CHMP Positive Opinion for Adjuvant Use in High-Risk CSCC Based on Phase X C-POST trial: XX% risk reduction in recurrence or death Already approved by U.S. FDA earlier this month #Regeneron #Libtayo #CHMP #EMA #CSCC #Oncology #Immunotherapy #CancerResearch #Biotech"  
[X Link](https://x.com/stellanewslife/status/1979541914698604705) [@stellanewslife](/creator/x/stellanewslife) 2025-10-18T13:35Z XXX followers, XX engagements


"Astellas to Present First Real-World VEOZAH (fezolinetant) Data at 2025 Annual Meeting of The Menopause Society Six posters including three late-breaking abstracts will be presented showcasing fezolinetants real-world impact on vasomotor symptoms (VMS) and work productivity among menopausal women. This reinforces Astellas' commitment to advancing womens health through non-hormonal innovation. 🔗 Full press release: #Astellas #VEOZAH #Fezolinetant #TMS2025 #Menopause #WomenInHealth #RealWorldEvidence #HotFlashes"  
[X Link](https://x.com/stellanewslife/status/1979547099806240965) [@stellanewslife](/creator/x/stellanewslife) 2025-10-18T13:56Z XXX followers, XX engagements


"👁 On World Sight Day 2025 Santen Pharmaceutical mobilized employees in nearly XX countries to support visually impaired individuals via the Be My Eyes app responding to XXX requests in XX languages. This marks the third year of the initiative. Read more: This global volunteering effort reflects the companys commitment to its philosophy: Happiness with Vision. #WorldSightDay #GlobalVolunteering #InclusionAndAccessibility"  
[X Link](https://x.com/stellanewslife/status/1979612513521299628) [@stellanewslife](/creator/x/stellanewslife) 2025-10-18T18:16Z XXX followers, XX engagements